H3B 8800

Drug Profile

H3B 8800

Alternative Names: H3B-8800

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator H3 Biomedicine
  • Developer Eisai Inc; H3 Biomedicine
  • Class Antineoplastics; Small molecules
  • Mechanism of Action SF3B1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Chronic myelomonocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 14 Aug 2017 H3B 8800 receives Orphan Drug status for Acute myeloid leukaemia in USA
  • 14 Aug 2017 H3B 8800 receives Orphan Drug status for Chronic myelomonocytic leukaemia in USA
  • 03 Dec 2016 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia and Chronic myelomonocytic leukemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top